片仔癀: 漳州片仔癀药业股份有限公司关于投资参与高鑫润信基金暨关联交易的公告

Core Viewpoint - The company plans to invest in the Gao Xin Run Xin Fund, focusing on the healthcare sector, with an investment amount of RMB 200 million, representing 20% of the fund's target size of RMB 1 billion [1][3][20]. Investment Overview - The Gao Xin Run Xin Fund will primarily invest in the healthcare sector, including pharmaceuticals, medical devices, and health-related supply chains, with non-healthcare investments capped at 10% of the fund's total contributions [1][19]. - The investment will be made by the company's wholly-owned subsidiary, Zhangzhou Pian Zai Huang Investment Management Co., Ltd., as a limited partner [1][3]. Related Transactions - This investment constitutes a related party transaction with Zhangzhou Pian Zai Huang Asset Management Co., Ltd. and Zhangzhou Tourism Investment Group Co., Ltd., but does not qualify as a major asset restructuring under relevant regulations [2][4]. - In the past 12 months, the company has engaged in two transactions with the same related party, totaling RMB 400 million, excluding this investment [2][4]. Approval Process - The investment has been approved by the company's independent directors and the board of supervisors, with related directors abstaining from voting [2][21][23]. - The investment does not require approval from the shareholders' meeting [2][21]. Financial Impact - The investment is not expected to have a significant impact on the company's financial status or operating performance for the current year [2][20]. - The company will not consolidate the Gao Xin Run Xin Fund into its financial statements [3][20]. Management and Compliance - The fund's management will be handled by CITIC Jin Investment Management Co., Ltd., which has extensive experience in the healthcare investment sector [20]. - The fund's investment decisions will require approval from an investment decision committee, ensuring compliance with legal and regulatory standards [16][19]. Purpose and Strategic Importance - The investment aims to enhance the company's core competitiveness and facilitate resource sharing and synergy within the healthcare industry [20]. - The company seeks to leverage the expertise of professional investment institutions to accelerate growth and innovation in the pharmaceutical sector [20].